株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaLeaders:中堅バイオテクノロジー企業のベンチマークレポート − 革新的事業者の売上予測・製品評価

PharmaLeaders: Mid-Cap Biotechnology Benchmark Report - Sales Forecasts and Product Valuations of Innovative Biotechs

発行 GlobalData 商品コード 262525
出版日 ページ情報 英文 222 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaLeaders:中堅バイオテクノロジー企業のベンチマークレポート − 革新的事業者の売上予測・製品評価 PharmaLeaders: Mid-Cap Biotechnology Benchmark Report - Sales Forecasts and Product Valuations of Innovative Biotechs
出版日: 2015年03月06日 ページ情報: 英文 222 Pages
概要

当レポートでは、独自のランキング手法によって選出した中堅バイオテクノロジー企業35社の動向について調査し、バイオテクノロジー業界全体の主要動向、過去数年の承認薬、「特許の崖」の影響、企業間の主な提携・買収戦略、財務状況の分析および比較、主要10社の上市済み製品、主要製品の売上予測、主要製品の純現在価値、臨床パイプラインなどをまとめています。

第1章 目次

第2章 イントロダクション

第3章 市場力学

  • バイオテクノロジー業界のファンダメンタルズ
  • 新たなFDA承認薬
  • 希少疾病用医薬品:もはや類まれな機会ではない
  • 「特許の崖 」:大幅に損なわれる売上

第4章 提携・買収戦略

  • 契約環境
    • 概要
    • 治療領域
  • M&A分析
    • 概要
    • 主な事業者
  • ライセンシング&パートナー契約
    • 概要
    • 主な事業者

第5章 財務管理

  • 収益
  • 前年比収益成長率
  • 営業収益
  • 粗利益率
  • 費用業績メトリクス
  • 流動性・評価メトリクス

第6章 企業分析

  • Acadia
  • Actelion
  • Alexion
  • BioMarin
  • Cubist
  • Incyte
  • Medivation
  • Pharmacyclics
  • Regeneron
  • Vertex
    • 上市済み製品
    • 主要製品の売上予測
    • 主要製品の純現在価値・DCF
    • 臨床パイプライン、など

第7章 将来の展望

第8章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC006PLR

GlobalData's "PharmaLeaders: Mid-Cap Biotechnology Benchmark Report - Sales Forecasts and Product Valuations of Innovative Biotechs" applies our proprietary ranking methodology to compare the competitive positions of 35 mid-cap biotechnology companies on 14 financial metrics. These companies are analyzed based on their financial performance, research and development (R&D) spending, capital structure, and firm utilization to illustrate the different strategies they are using to increase value for their shareholders and create a competitive advantage. Throughout the report, GlobalData's Industry Dynamics Team provides expert insight, expanding on each of the metrics discussed.

In addition to the financial metrics, this report provides an overview of the biotech sector growth rates, and discusses the regulatory approvals that occurred in 2014, along with our forecast sales outlook for each drug. We also examine how the patent cliff will impact the industry moving forward, along with deals and licensing activity, and the prospects for niche/orphan drugs. Lastly, we use our proprietary database tools to determine the Net Present Value (NPV) of both marketed and clinical pipeline assets and their future profits and cash flows.

Highlights

Key Questions Answered

  • What specific strategies are these innovative biotech companies employing to gain market share?
  • What therapeutic areas are these biotech companies focusing their R&D spending?
  • Which trends will affect the biotech sector moving forward?
  • How does my pipeline and commercialization strategy match up against the competition?
  • What specific business development activities are taking place, in terms of partnerships or M&A?
  • What particular enabling technologies and drug platforms are these biotech companies developing?
  • How are these biotech companies maximizing their capital spend to gain a competitive advantage?

Scope

  • This report provides analysis of the key drivers and trends shaping the biotechnology sector; including drivers of financial growth and R&D spending, FDA approvals, generic erosion, corporate strategy, orphan drugs and asset value creation
  • This report offers a deep dive into the synergies behind partnering and acquisition activity
  • FDA expedited review - drugs approved by Fast Track, Breakthrough, Priority Review, and Accelerated approval pathways
  • Six-year forecasts for key drugs approved in 2014; Net Present Value (NPV) for key drugs approved in 2014.

Reasons to buy

  • Analyze and track the strategies that these drug companies are using to gain share in the increasingly competitive market
  • Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending and asset structure
  • Organize your sales and marketing strategy to identify companies with proprietary technologies in order to maximize opportunities for licensing, partnership, equity investment or takeover
  • Independent source to benchmark your company's performance against a similar peer group to assess areas of strength/weakness

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Report Scope
  • 2.2. Companies Covered
  • 2.3. Upcoming Reports
  • 2.4. Recently Published Reports

3. Market Dynamics

  • 3.1. Sector Fundamentals
    • 3.1.1. Growth Rate
    • 3.1.2. R&D Spending
    • 3.1.3. Company Outlook
    • 3.1.4. Sales Forecasts
    • 3.1.5. Product Valuations
  • 3.2. FDA Approved 41 New Drugs in 2014
    • 3.2.1. Drugs Approved in 2014
    • 3.2.2. Multiple Approval Pathways Expedite Review of Innovatie Medicines
    • 3.2.3. CDER Continues to Meet PDUFA Goal Dates for Review Cycles
    • 3.2.4. GlobalData's Forecast for 2014 Approvals: BMS' Opdivo Projected to be Top Seller
  • 3.3. Orphan Drugs: No Longer a Rare Opportunity
    • 3.3.1. Historic Number of Orphan Drugs Approved in 2014
    • 3.3.2. Orphan Drugs Approved in 2014
    • 3.3.3. Celgene's Revlimid Will Eclipse Roche's MabThera/Rituxan by 2018
  • 3.4. FDA Approved 27 New Drugs in 2013
    • 3.4.1. Drugs Approved in 2013
    • 3.4.2. GlobalData's Sales Forecasts for Drugs Approved in 2013
    • 3.4.3. NME Approvals Drive Much Needed Value in the Pharmaceutical Market
    • 3.4.4. Exceptional Uptake of Sovaldi and Tecfidera Paves the Way for New Optimism in Pharma
  • 3.5. Patent Cliff to Erode $65 Billion in Sales by 2019
    • 3.5.1. Top Patent Expiries

4. Collaboration and Acquisition Strategies

  • 4.1. Deals Landscape
    • 4.1.1. Overview
    • 4.1.2. Therapeutic Analysis
  • 4.2. M&A Analysis
    • 4.2.1. Overview
    • 4.2.2. Top Spenders
  • 4.3. Licensing and Partnership Deals
    • 4.3.1. Overview
    • 4.3.2. Top Spenders

5. Financial Management

  • 5.1. Revenue
    • 5.1.1. Regeneron, Actelion, and Alexion
  • 5.2. Year-to-Year Revenue Growth
    • 5.2.1. Peer Group Leaders
    • 5.2.2. Theravance and Vertex
  • 5.3. Operating Income
    • 5.3.1. Regeneron, Jazz, and Salix
    • 5.3.2. Ironwood
  • 5.4. Gross Profit Margin
    • 5.4.1. Peer Group Leaders
  • 5.5. Expense Performance Metrics
    • 5.5.1. R&D Spending
    • 5.5.2. R&D Spending Growth
    • 5.5.3. SG&A Margin
  • 5.6. Liquidity and Valuation Metrics
    • 5.6.1. Capital Expenditures
    • 5.6.2. Cash and Marketable Securities
    • 5.6.3. Total Debt
    • 5.6.4. Total Assets
    • 5.6.5. Cash Ratio
    • 5.6.6. Market Capitalization
    • 5.6.7. Enterprise Value

6. Company Analysis

  • 6.1. Acadia
    • 6.1.1. Marketed Products
    • 6.1.2. Nuplazid Sales Forecast
    • 6.1.3. Nuplazid NPV & DCF
    • 6.1.4. Clinical Pipeline
  • 6.2. Actelion
    • 6.2.1. Marketed Products
    • 6.2.2. Opsumit and Tracleer Sales Forecasts
    • 6.2.3. Opsumit NPV & DCF
    • 6.2.4. Clinical Pipeline
  • 6.3. Alexion
    • 6.3.1. Marketed Products
    • 6.3.2. Soliris Sales Forecast
    • 6.3.3. Soliris NPV & DCF
    • 6.3.4. Clinical Pipeline
  • 6.4. BioMarin
    • 6.4.1. Marketed Products
    • 6.4.2. Naglazyme and BioMarin Sales Forecasts
    • 6.4.3. Naglazyme NPV & DCF
    • 6.4.4. Clinical Pipeline
  • 6.5. Cubist
    • 6.5.1. Marketed Products
    • 6.5.2. Cubicin Sales Forecast
    • 6.5.3. Cubicin NPV & DCF
    • 6.5.4. Clinical Pipeline
  • 6.6. Incyte
    • 6.6.1. Marketed Products
    • 6.6.2. Jakafi Sales Forecast
    • 6.6.3. Jakafi NPV & DCF
    • 6.6.4. Clinical Pipeline
  • 6.7. Medivation
    • 6.7.1. Marketed Products
    • 6.7.2. Xtandi Sales Forecast
    • 6.7.3. Xtandi NPV & DCF
    • 6.7.4. Clinical Pipeline
  • 6.8. Pharmacyclics
    • 6.8.1. Marketed Products
    • 6.8.2. Imbruvica Sales Forecast
    • 6.8.3. Imbruvica NPV & DCF
    • 6.8.4. Clinical Pipeline
  • 6.9. Regeneron
    • 6.9.1. Marketed Products
    • 6.9.2. Eylea Sales Forecast
    • 6.9.3. Eylea NPV & DCF
    • 6.9.4. Clinical Pipeline
  • 6.10. Vertex
    • 6.10.1. Marketed Products
    • 6.10.2. Kalydeco Sales Forecast
    • 6.10.3. Kalydeco NPV & DCF
    • 6.10.4. Clinical Pipeline

7. Future Outlook

8. Appendix

  • 8.1. Research Methodology
    • 8.1.1. Coverage
    • 8.1.2. Secondary Research
  • 8.2. About the Author
    • 8.2.1. Adam Dion, Industry Analyst
  • 8.3. Director, Healthcare Industry Dynamics
  • 8.4. Global Head of Healthcare
  • 8.5. About the Industry Dynamics Team
  • 8.6. About GlobalData
  • 8.7. Disclosure Information
  • 8.8. Disclaimer

List of Tables

  • Table 1: Pharmaceutical Industry, Sector Revenues ($bn) and CAGRs, 2011-2019
  • Table 2: Pharmaceutical Industry, Sector R&D Spending ($bn), 2008-2013
  • Table 3: Biotech Peer Group, Company Forecasts ($m), 2014-2019
  • Table 4: Biotech Peer Group, Product Forecasts ($m), 2013-2019
  • Table 5: NMEs Approved By the CDER, 2014
  • Table 6: Sales Forecasts ($m) for Key NME Approvals in 2014, 2014-2019
  • Table 7: Orphan Drug Approvals, 2014
  • Table 8: NMEs Approved in 2013
  • Table 9: Sales Forecasts ($m) for Key NME Approvals in 2013, 2014-2019
  • Table 10: Top Patent Expiries, Sales ($m), 2013-2019
  • Table 11: Biotechnology Sector, Headline M&A Deals, 2014
  • Table 12: Biotechnology Sector, Headline M&A Deals, 2013
  • Table 13: Salix, M&A Deals, Summary, 2005-2014
  • Table 14: Salix, M&A Deals, Financials, 2005-2014
  • Table 15: Sumitomo Dainnipon, M&A Deals, Summary, 2009-2014
  • Table 16: Sumitomo Dainippon, M&A Deals, Financials, 2009-2014
  • Table 17: Jazz, M&A Deals, Summary, 2011-2014
  • Table 18: Jazz, M&A Deals, Financials, 2011-2014
  • Table 19: Cubist, M&A Deals, Summary, 2009-2014
  • Table 20: Cubist, M&A Deals, Financials, 2007-2014
  • Table 21: Alexion, M&A Deals, Summary, 2008-2014
  • Table 22: Alexion, M&A Deals, Financials, 2006-2014
  • Table 23: Biotechnology Sector, Headline Licensing and Partnership Deals, 2014
  • Table 24: Biotechnology Sector, Headline Licensing and Partnership Deals, 2014 (Cont'd)
  • Table 25: Biotechnology Sector, Headline Licensing and Partnership Deals, 2013
  • Table 26: H. Lundbeck, Licensing Deals, Summary, 2008-2014
  • Table 27: H. Lundbeck, Licensing Deals, Financials, 2008-2014
  • Table 28: Isis, Licensing Deals, Summary, 2008-2014
  • Table 29: Isis, Licensing Deals, Financials, 2008-2014
  • Table 30: Seattle Genetics, Licensing Deals, Summary, 2009-2014
  • Table 31: Seattle Genetics, Licensing Deals, Financials, 2007-2014
  • Table 32: Alnylam, Licensing Deals, Summary, 2007-2014
  • Table 33: Alnylam, Licensing Deals, Financials, 2007-2014
  • Table 34: Regeneron, Licensing Deals, Summary, 2006-2014
  • Table 35: Regeneron, Licensing Deals, Financials, 2005-2014
  • Table 36: Acadia, Marketed Product Overview
  • Table 37: Nuplazid, Product Details
  • Table 38: Nuplazid, Milestone Details, 2012-2014
  • Table 39: Nuplazid, NPV Parameters
  • Table 40: Actelion, Marketed Products Overview
  • Table 41: Opsumit, Product Details
  • Table 42: Opsumit, Milestone Details, 2013-2014
  • Table 43: Opsumit, NPV Parameters
  • Table 44: Alexion, Marketed Product Overview
  • Table 45: Soliris, Product Details
  • Table 46: Soliris, Milestone Details, 2014
  • Table 47: Soliris, NPV Parameters
  • Table 48: BioMarin, Marketed Products Overview
  • Table 49: Naglazyme, Product Details
  • Table 50: Naglazyme, Milestone Details, 2005-2009
  • Table 51: Naglazyme, NPV Parameters
  • Table 52: Cubist, Marketed Products Overview
  • Table 53: Cubicin, Product Details
  • Table 54: Cubicin, Milestone Details, 2011-2014
  • Table 55: Cubicin, NPV Parameters
  • Table 56: Incyte, Marketed Product Overview
  • Table 57: Jakafi, Product Details
  • Table 58: Jakafi, Milestone Details, 2014
  • Table 59: Jakafi, NPV Parameters
  • Table 60: Medivation, Marketed Product Overview
  • Table 61: Xtandi, Product Details
  • Table 62: Xtandi, Milestone Details, 2014
  • Table 63: Xtandi, NPV Parameters
  • Table 64: Pharmacyclics, Marketed Product Overview
  • Table 65: Imbruvica, Product Details
  • Table 66: Imbruvica, Milestone Details, 2014
  • Table 67: Imbruvica, NPV Parameters
  • Table 68: Regeneron, Marketed Products Overview
  • Table 69: Eylea, Product Details
  • Table 70: Eylea, Milestone Details, 2014
  • Table 71: Eylea, NPV Parameters
  • Table 72: Vertex, Marketed Products Overview
  • Table 73: Kalydeco, Product Details
  • Table 74: Kalydeco, Milestone Details, 2013-2014
  • Table 75: Kalydeco, NPV Parameters

List of Figures

  • Figure 1: Mid-Cap Biotech Peer Group, Revenue ($m) and Growth Rate, 2009-2013
  • Figure 2: Mid-Cap Biotech Peer Group, Revenue ($m) and Average Gross Margin, 2008-2013
  • Figure 3: Mid-Cap Biotech Peer Group, R&D Spending ($m) and Growth Rate 2009-2013
  • Figure 4: Global Marketed Product and Pipeline Sales ($m) Contributions, 2019
  • Figure 5: Total Pharmaceutical Market Pipeline Revenue ($m), 2014-2019
  • Figure 6: Mid-Cap Biotech Peer Group, Company Sales ($m), 2013 vs. 2019
  • Figure 7: Mid-Cap Biotech Peer Group, Product Forecasts ($m), 2019
  • Figure 8: Mid-Cap Biotech Peer Group, Leading Products, NPV ($m)
  • Figure 9: Number of NMEs Filed With and Approved by the CDER, 2004-2014
  • Figure 10: Number of BLAs Approved by CDER, 2004-2014
  • Figure 11: CDER Median Total Time (Months) to Drug Approval, Priority Review, 1993-2014
  • Figure 12: Status of CDER Breakthrough Therapy Requests, 2014
  • Figure 13: Percentage of Total Breakthrough Therapy Requests By Therapeutic Area, 2014
  • Figure 14: Percentage of Total Breakthrough Therapy Approvals By Therapeutic Area, 2014
  • Figure 15: Percentage of Total NMEs Approved by the CDER by Pathway, 2011-2014
  • Figure 16: Percentage of Total NMEs Approved During the First Review Cycle and First in the US, 2011-2014
  • Figure 17: Net Present Value ($m) for Key Approvals, 2014
  • Figure 18: Number of Orphan Drugs Approved, 1983-2014
  • Figure 19: Orphan Drug Peer Group Forecast ($m), 2009-2019
  • Figure 20: Leading Orphan Drug Sales ($m), Top 25, 2019
  • Figure 21: Leading Orphan Drug Sales ($m), Cont'd, 2019
  • Figure 22: Revlimid vs. MabThera/Rituxan Sales ($m), 2006-2019
  • Figure 23: Combined Revenue ($m) Projections for 2013 vs. 2012 FDA Approvals, 2012-2019
  • Figure 24: First Full-Year Sales ($m) for Major Product Launches by Year, 2009-2013
  • Figure 25: Revenue ($m) Projections for 2013 FDA Approvals, 2014-2019
  • Figure 26: Patent Cliff Sales ($m) Erosion, 2013-2019
  • Figure 27: Biotechnology Sector, Total M&As and Licensing Deals and Deal Values ($m), 2009-2014
  • Figure 28: Biotechnology Sector, Total and Average Milestone Payments ($m), 2010-2014
  • Figure 29: Biotechnology Sector, Total and Average Upfront Payments ($m), 2010-2014
  • Figure 30: Biotechnology Sector, Total Number of Deals by Therapy Area, 2010-2014
  • Figure 31: Biotechnology Sector, Distribution (%) of Deals by Therapy Area, 2010-2014
  • Figure 32: Biotechnology Sector, Total Deal Value ($m) by Therapy Area, 2010-2014
  • Figure 33: Biotechnology Sector, Number of M&A Deals and Deal Values ($m), 2009-2014
  • Figure 34: Biotechnology Sector, M&A Deal Values ($m) by Company, 2010-2014
  • Figure 35: Biotechnology Sector, Total Number of Licensing Deals and Deal Values ($m), 2009-2014
  • Figure 36: Biotechnology Sector, Licensing and Partnership Deal Values ($m) by Company, 2010-2014
  • Figure 37: Revenue ($m) by Company, 2013
  • Figure 38: Revenue Growth (%) by Company, 2013
  • Figure 39: Operating Income ($m) by Company, 2013
  • Figure 40: Gross Profit Margin (%) by Company, 2013
  • Figure 41: R&D Spending ($m) by Company, 2013
  • Figure 42: R&D Spending Growth (%) By Company, 2013
  • Figure 43: SG&A Spending (%) of Revenue by Company, 2013
  • Figure 44: Capex ($m) by Company, 2013
  • Figure 45: Cash and Marketable Securities ($m) by Company, 2013
  • Figure 46: Total Debt ($m) by Company, 2013
  • Figure 47: Total Assets ($m) by Company, 2013
  • Figure 48: Cash Ratio (%) by Company, 2013
  • Figure 49: Market Capitalization ($m) by Company
  • Figure 50: Enterprise Value ($m) by Company
  • Figure 51: Nuplazid Sales Forecast ($m), 2015-2019
  • Figure 52: Nuplazid Net Present Value ($m)
  • Figure 53: Nuplazid Net Profit and DCF ($m), 2015-2029
  • Figure 54: Acadia, Number of Pipeline Products vs. Number of Clinical Trials
  • Figure 55: Nuplazid, Number of Clinical Trials
  • Figure 56: Acadia, Number of Clinical Trials in Late-Stage by Therapy Area
  • Figure 57: Acadia, Percentage of Late-Stage Pipeline
  • Figure 58: Acadia, Number of Clinical Trials by Phase
  • Figure 59: Acadia, Number of Clinical Trials by Indication, CNS Disorders
  • Figure 60: Opsumit and Tracleer Sales Forecasts ($m), 2006-2019
  • Figure 61: Actelion Total Revenue and Forecast ($m), 2006-2019
  • Figure 62: Opsumit, Net Present Value ($m)
  • Figure 63: Opsumit, Net Profit and DCF ($m), 2014-2029
  • Figure 64: Actelion, Number of Pipeline Products vs. Number of Clinical Trials
  • Figure 65: Actelion, Number of Clinical Trials
  • Figure 66: Actelion, Number of Clinical Trials in Late-Stage by Therapy Area
  • Figure 67: Actelion, Percentage of Late-Stage Pipeline
  • Figure 68: Actelion, Number of Clinical Trials by Phase
  • Figure 69: Actelion, Number of Clinical Trials by Indication, Cardiovascular Disorders
  • Figure 70: Soliris Sales Forecast ($m), 2007-2019
  • Figure 71: Alexion, Revenue and Forecast ($m), 2009-2019
  • Figure 72: Soliris, Net Present Value ($m)
  • Figure 73: Soliris, Net Profit and DCF ($m), 2014-2029
  • Figure 74: Alexion, Number of Pipeline Products vs. Number of Clinical Trials
  • Figure 75: Soliris, Number of Clinical Trials
  • Figure 76: Alexion, Number of Clinical Trials in Late-Stage by Therapy Area
  • Figure 77: Alexion, Percentage of Late-Stage Pipeline
  • Figure 78: Alexion, Number of Clinical Trials by Phase
  • Figure 79: Naglazyme Sales Forecast ($m), 2008-2019
  • Figure 80: BioMarin Total Revenue and Forecast ($m), 2008-2019
  • Figure 81: Naglazyme, NPV ($m)
  • Figure 82: Naglazyme, Net Profit and DCF ($m), 2014-2029
  • Figure 83: BioMarin, Number of Pipeline Products vs. Number of Clinical Trials
  • Figure 84: BioMarin, Marketed Products Clinical Trials
  • Figure 85: BioMarin, Number of Clinical Trials by Therapy Area
  • Figure 86: BioMarin, Percentage of Late-Stage Pipeline
  • Figure 87: BioMarin, Number of Clinical Trials by Phase
  • Figure 88: BioMarin, Number of Clinical Trials by Indication, Metabolic Disorders
  • Figure 89: Cubicin Sales Forecast ($m), 2008-2019
  • Figure 90: Cubist Revenue and Forecast ($m), 2008-2019
  • Figure 91: Cubicin NPV ($m)
  • Figure 92: Cubicin Net Profit and DCF ($m), 2014-2022
  • Figure 93: Cubist, Number of Pipeline Products vs. Number of Clinical Trials
  • Figure 94: Cubist, Marketed Products Clinical Trials
  • Figure 95: Cubist, Percentage of Late-Stage Pipeline
  • Figure 96: Cubist, Number of Clinical Trials in Late-Stage by Therapy Area
  • Figure 97: Cubist, Number of Clinical Trials by Phase
  • Figure 98: Cubist, Number of Clinical Trials by Indication, Infectious Diseases
  • Figure 99: Jakafi Sales Forecast ($m), 2012-2019
  • Figure 100: Jakafi NPV ($m)
  • Figure 101: Jakafi, Net Profit and DCF ($m), 2014-2029
  • Figure 102: Incyte, Number of Pipeline Products vs. Number of Clinical Trials
  • Figure 103: Incyte, Marketed Products Clinical Trials
  • Figure 104: Incyte, Number of Clinical Trials in Late-Stage by Therapy Area
  • Figure 105: Incyte, Percentage of Late-Stage Pipeline
  • Figure 106: Incyte, Number of Clinical Trials by Phase
  • Figure 107: Incyte, Number of Clinical Trials in Late-Stage by Indication, Hematology
  • Figure 108: Xtandi Sales Forecast ($m), 2012-2019
  • Figure 109: Xtandi NPV ($m)
  • Figure 110: Xtandi Net Profit and DCF ($m), 2014-2029
  • Figure 111: Medivation, Number of Pipeline Products vs. Number of Clinical Trials
  • Figure 112: Medivation, Marketed Products Clinical Trials
  • Figure 113: Medivation, Percentage of Late-Stage Pipeline
  • Figure 114: Medivation, Number of Clinical Trials in Late-Stage by Therapy Area
  • Figure 115: Medivation, Number of Clinical Trials by Phase
  • Figure 116: Medivation, Number of Clinical Trials in Late-Stage by Indication, Oncology and CNS
  • Figure 117: Imbruvica Sales Forecast ($m), 2013-2019
  • Figure 118: Imbruvica NPV ($m)
  • Figure 119: Imbruvica Net Profit and DCF ($m), 2014-2029
  • Figure 120: Pharmacyclics, Number of Pipeline Products vs. Number of Clinical Trials
  • Figure 121: Pharmacyclics, Marketed Products Clinical Trials
  • Figure 122: Pharmacyclics, Percentage of Late-Stage Pipeline
  • Figure 123: Pharmacyclics, Number of Clinical Trials in Late-Stage by Therapy Area
  • Figure 124: Pharmacyclics, Number of Clinical Trials by Phase
  • Figure 125: Pharmacyclics, Number of Clinical Trials in Late-Stage by Indication, Oncology
  • Figure 126: Eylea Sales Forecast ($m), 2012-2019
  • Figure 127: Regeneron Revenue Forecast ($m), 2012-2019
  • Figure 128: Eylea NPV ($m),
  • Figure 129: Eylea Net Profit and DCF ($m), 2014-2029
  • Figure 130: Regeneron, Number of Pipeline Products vs. Number of Clinical Trials
  • Figure 131: Regeneron, Marketed Products Clinical Trials
  • Figure 132: Regeneron, Percentage of Late-Stage Pipeline
  • Figure 133: Regeneron, Number of Clinical Trials in Late-Stage by Therapy Area
  • Figure 134: Regeneron, Number of Clinical Trials by Phase
  • Figure 135: Regeneron, Number of Clinical Trials by Indication, Ophthalmology
  • Figure 136: Regeneron, Selected Product NPVs
  • Figure 137: Kalydeco Sales Forecast ($m), 2012-2019
  • Figure 138: Kalydeco NPV ($m)
  • Figure 139: Kalydeco, Net Profit and DCF ($m), 2014-2029
  • Figure 140: Vertex, Number of Pipeline Products vs. Number of Clinical Trials
  • Figure 141: Vertex, Marketed Products Clinical Trials
  • Figure 142: Vertex, Percentage of Late-Stage Pipeline
  • Figure 143: Vertex, Number of Clinical Trials in Late-Stage by Therapy Area
  • Figure 144: Vertex, Number of Clinical Trials by Phase
  • Figure 145: Vertex, Number of Clinical Trials in Late-Stage by Indication
Back to Top